A Phase II Randomized, Multicenter, Open-Label Trial of Continuing Adjuvant Temozolomide Beyond Six Cycles in Patients With Glioblastoma (GEINO 14-01)

Research paper from Neuro-Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

These clinical trial results suggest that six cycles of temozolomide is as effective as 12 for patients with glioblastoma and produces fewer side effects.

Go to full paper published in Neuro-Oncology.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.